Very recently, a phase 1 open-label study tested ivosidenib or enasidenib in combination with induction chemotherapy in patients with either IDH1- or IDH2-mutated newly diagnosed AML [98]. The gene discussed is IDH2; the disease is acute myeloid leukemia.